Mobilise-D: Extension Study

Parkinson Disease Clinical Trial

Official title:

Validating a Digital Mobility Assessment in Parkinson's Disease Using Wearable Technology - the Mobilise-D Extension Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05874739
• Other study ID #: 10402
• Secondary ID: MJFF-022735MJFF-
• Status: Recruiting
• Start date: May 17, 2023
• Est. completion date: July 28, 2025

Study information

• Verified date: January 2024
• Source: Newcastle-upon-Tyne Hospitals NHS Trust
• Contact: Isabel K Neatrour, MSc
• Phone: +44 (0) 191 2081406
• Email: isabel.neatrour[@]newcastle.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to investigate the ability of a mobility monitor to measure and predict outcomes in Parkinson's disease (PD). It is an extension of a previous study (the Mobilise-D Clinical Validation Study) and consists of an additional follow-up visit for PD participants and the recruitment of age matched control participants. The data will inform researchers about PD disease progression and normal changes in mobility associated with aging.

Description:

This study is an extension to the Mobilise-D project which aims to develop a real world digital assessment of mobility. This Extension Study will build on the work of the Clinical Validation Study (CVS) to extend the follow-up period of the Parkinson's disease (PD) cohort and to recruit an age matched control cohort. The additional data will for allow for modelling of disease progression in PD over a longer time period and inform on progression in normal ageing. The Mobilise-D Extension Study is an observational cohort study taking place at five clinical sites across four different countries. The study will recruit up to 551 PD participants from the CVS PD cohort and 200 age and gender matched control participants. The PD participants will attend a single follow-up visit 36 months after their initial CVS baseline visit. The control participants will attend a baseline visit and a 12-month follow-up visit. All study visits consist of the collection of descriptive, clinical, physical, neuropsychological data. Following each visit, participants are required to wear a body worn sensor for seven days continual monitoring. A small sample of participants will be invited to take part in a semi-structured interview (Qualitative Sub Study) to better understand participants' experiences of PD symptoms and the impact they have on mobility. The investigators also want to know if the aspects of mobility that are being measured are relevant to people with PD. These interviews will take place face to face or remotely, depending on preference.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 751
• Est. completion date: July 28, 2025
• Est. primary completion date: July 28, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Control Cohort:

Inclusion Criteria:

• Aged 50 years or over
• Able to walk 4 meters independently without walking aids
• Anticipated availability for 12 months.
• Ability to consent and comply with any study specific procedures.
• Willingness to wear a wearable sensor for mobility monitoring
• Able to read and write in first language in the respective country

Exclusion Criteria:

• Occurrence of any of the following within 3 months prior to informed consent:

myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological or orthopaedic impairment that significantly impacts on gait

• Patients with a clinical diagnosis of PD, COPD, proximal hip fracture or MS
• History of dementia/significant cognitive impairment, or movement disorder (including essential tremor) PD Cohort

Inclusion Criteria:

• Participant in the Mobilise-D Clinical Validation Study (CVS) PD Cohort - see below. CVS PD Cohort:

Inclusion criteria:

• Aged 18 or over
• Patients with the clinical diagnosis of PD according to the recent criteria of the Movement Disorder Society
• Hoehn & Yahr stage I-III

Exclusion Criteria:

• History consistent with Dementia with Lewy Bodies (DLB), atypical parkinsonian syndromes (including multiple system atrophy or progressive supranuclear palsy, diagnosed according to accepted criteria)
• Repeated strokes or stepwise progression of symptoms, leading to a diagnosis of 'vascular parkinsonism'
• Drug-induced Parkinsonism

Related Conditions & MeSH terms

• Aging
• Parkinson Disease

Locations

Country	Name	City	State
United Kingdom	The Newcastle upon Tyne Hospitals NHS Foundation Trust	Newcastle upon Tyne

Sponsors (6)

Lead Sponsor	Collaborator
Newcastle-upon-Tyne Hospitals NHS Trust	KU Leuven, Tel-Aviv Sourasky Medical Center, University College Dublin, University Hospital Erlangen, University of Kiel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in LLFDI in controls	Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) in control data. This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).	12 months
Primary	Change in LLFDI in PD	Change in the functional component score of the Late-Life Functional Disability Index (LLFDI) in PD data. This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).	36 months
Primary	Change in fall frequency in PD	Change in fall frequency (in previous 6 months) in PD data	36 months
Secondary	Difference in Real Walking Speed	Assess difference in Real Walking Speed between PD and control data as measured using a body worn sensor during a 7-day digital mobility assessment (DMA)	36 months (PD) and 12 months (control)
Secondary	Fall frequency in controls	Change in fall frequency (in previous 6 months) in control data	12 months
Secondary	Ability of Real Walking Speed to detect change in PD severity	Ability of Real Walking Speed (measured through digital mobility assessment) to detect change in PD disease severity as measured by the MDS Unified Parkinson's Disease Rating Scale (UPDRS). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).	36 months
Secondary	Ability of Real Walking Speed to predict change in physical capacity	Ability of Real Walking Speed (measured through digital mobility assessment) to detect change in physical capacity in PD and control data, as measured through the Late-Life Functional Disability Index (LLFDI). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).	36 months (PD) and 12 months (control)
Secondary	Ability of Real Walking Speed to predict change in PD severity	Ability of Real Walking Speed (measured through digital mobility assessment) to predict change in PD disease severity as measured by the MDS Unified Parkinson's Disease Rating Scale (UPDRS). This assessment has 32 items, each with a scale from 5 (no difficulty) to 1 (unable to do). Raw scores are transformed into summary scores ranging from 0 (low level in ability) to 100 (high level of ability).	36 months